ArticleJCO precision oncology2018
Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States.
Abstract read
In one paragraph
Article in JCO precision oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Barriers and facilitators to next-generation sequencing use in United States oncology settings: a systematic review.Future oncology (London, England) · 2024Pooled it
- Copy number of 8q24.3 drives HSF1 expression and patient outcome in cancer: an individual patient data meta-analysis.Human genomics · 2019Pooled it
- Implementation of a pharmacogenetic panel-based test for pharmacotherapy-based supportive care in an adult oncology clinic.Clinical and translational science · 2024Trial
- Molecular Tumor Board-Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial.JCO precision oncology · 2022Trial
- Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.JAMA oncology · 2021Trial
- Building a genomics-capable cancer workforce: a competency-based framework for education and training in precision oncology.EClinicalMedicine · 2026Review
- Molecular Tumor Board-Directed Treatment for Patients with Advanced-Stage Solid Tumors: A Case-Control Real-World Study.Current oncology (Toronto, Ont.) · 2026Observational
- Optimizing Precision Oncology: Structural Frameworks for Local MTB Integration and Outcome Assessment.Medical sciences (Basel, Switzerland) · 2026Review
- Integrating Somatic and Germline Pharmacogenomics for Therapeutic Decisions in Precision Oncology.JCO precision oncology · 2026Article
- Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United States.JAMA network open · 2026Article
- Unique Features of a Comprehensive Genomic Profiling Panel: Expanding Treatment Options in a Value-Based Community Oncology Network.JCO precision oncology · 2026Article
- Exploratory Identification of Gene Copy Number Cut-Off for NGS-BasedLung Cancer (Auckland, N.Z.) · 2026Article
- Advancing Precision Medicine in Non-Small Cell Lung Cancer Diagnostics in a Southeast Asian Country.Cancer management and research · 2026Article
- Molecular Genetics of Renal Cell Carcinoma: A Narrative Review Focused on Clinical Relevance.Current oncology (Toronto, Ont.) · 2025Review
- Tumor diagnosis recharacterization enabled by comprehensive genomic profiling to guide precision medicine strategy.NPJ precision oncology · 2025Article
- New horizons at the interface of artificial intelligence and translational cancer research.Cancer cell · 2025Review
- Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients.NPJ precision oncology · 2025Article
- Review
- Oncofusions - shaping cancer care.The oncologist · 2025Article
- The impact of integrated genomic analysis on molecular classifications and prognostic risk stratification in endometrial cancer: a Chinese experience.Frontiers in oncology · 2025Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Andrew N Freedman, , , , , , , and , National Cancer Institute; , Information Management Services, Rockville; , National Institutes of Health; , National Human Genome Research Institute, Bethesda; , Scientific Consulting Group, Gaithersburg, MD; , RTI International, Research Triangle Park, NC; , City of Hope, Duarte, CA; , Harvard Medical School and Brigham and Women's Hospital; , Dana-Farber Cancer Institute, Boston, MA; , University of Vermont Health Network and the University of Vermont, Burlington, VT; , Georgetown University, Washington, DC; , American Society of Clinical Oncology, Alexandria, VA; and , American Cancer Society, Atlanta, GA.
Carrie N Klabunde, , , , , , , and , National Cancer Institute; , Information Management Services, Rockville; , National Institutes of Health; , National Human Genome Research Institute, Bethesda; , Scientific Consulting Group, Gaithersburg, MD; , RTI International, Research Triangle Park, NC; , City of Hope, Duarte, CA; , Harvard Medical School and Brigham and Women's Hospital; , Dana-Farber Cancer Institute, Boston, MA; , University of Vermont Health Network and the University of Vermont, Burlington, VT; , Georgetown University, Washington, DC; , American Society of Clinical Oncology, Alexandria, VA; and , American Cancer Society, Atlanta, GA.
Kristine Wiant, , , , , , , and , National Cancer Institute; , Information Management Services, Rockville; , National Institutes of Health; , National Human Genome Research Institute, Bethesda; , Scientific Consulting Group, Gaithersburg, MD; , RTI International, Research Triangle Park, NC; , City of Hope, Duarte, CA; , Harvard Medical School and Brigham and Women's Hospital; , Dana-Farber Cancer Institute, Boston, MA; , University of Vermont Health Network and the University of Vermont, Burlington, VT; , Georgetown University, Washington, DC; , American Society of Clinical Oncology, Alexandria, VA; and , American Cancer Society, Atlanta, GA.
Lindsey Enewold, , , , , , , and , National Cancer Institute; , Information Management Services, Rockville; , National Institutes of Health; , National Human Genome Research Institute, Bethesda; , Scientific Consulting Group, Gaithersburg, MD; , RTI International, Research Triangle Park, NC; , City of Hope, Duarte, CA; , Harvard Medical School and Brigham and Women's Hospital; , Dana-Farber Cancer Institute, Boston, MA; , University of Vermont Health Network and the University of Vermont, Burlington, VT; , Georgetown University, Washington, DC; , American Society of Clinical Oncology, Alexandria, VA; and , American Cancer Society, Atlanta, GA.
Stacy W Gray, , , , , , , and , National Cancer Institute; , Information Management Services, Rockville; , National Institutes of Health; , National Human Genome Research Institute, Bethesda; , Scientific Consulting Group, Gaithersburg, MD; , RTI International, Research Triangle Park, NC; , City of Hope, Duarte, CA; , Harvard Medical School and Brigham and Women's Hospital; , Dana-Farber Cancer Institute, Boston, MA; , University of Vermont Health Network and the University of Vermont, Burlington, VT; , Georgetown University, Washington, DC; , American Society of Clinical Oncology, Alexandria, VA; and , American Cancer Society, Atlanta, GA.
Kelly K Filipski, , , , , , , and , National Cancer Institute; , Information Management Services, Rockville; , National Institutes of Health; , National Human Genome Research Institute, Bethesda; , Scientific Consulting Group, Gaithersburg, MD; , RTI International, Research Triangle Park, NC; , City of Hope, Duarte, CA; , Harvard Medical School and Brigham and Women's Hospital; , Dana-Farber Cancer Institute, Boston, MA; , University of Vermont Health Network and the University of Vermont, Burlington, VT; , Georgetown University, Washington, DC; , American Society of Clinical Oncology, Alexandria, VA; and , American Cancer Society, Atlanta, GA.
Nancy L Keating, , , , , , , and , National Cancer Institute; , Information Management Services, Rockville; , National Institutes of Health; , National Human Genome Research Institute, Bethesda; , Scientific Consulting Group, Gaithersburg, MD; , RTI International, Research Triangle Park, NC; , City of Hope, Duarte, CA; , Harvard Medical School and Brigham and Women's Hospital; , Dana-Farber Cancer Institute, Boston, MA; , University of Vermont Health Network and the University of Vermont, Burlington, VT; , Georgetown University, Washington, DC; , American Society of Clinical Oncology, Alexandria, VA; and , American Cancer Society, Atlanta, GA.
Debra G B Leonard, , , , , , , and , National Cancer Institute; , Information Management Services, Rockville; , National Institutes of Health; , National Human Genome Research Institute, Bethesda; , Scientific Consulting Group, Gaithersburg, MD; , RTI International, Research Triangle Park, NC; , City of Hope, Duarte, CA; , Harvard Medical School and Brigham and Women's Hospital; , Dana-Farber Cancer Institute, Boston, MA; , University of Vermont Health Network and the University of Vermont, Burlington, VT; , Georgetown University, Washington, DC; , American Society of Clinical Oncology, Alexandria, VA; and , American Cancer Society, Atlanta, GA.
Tracy Lively, , , , , , , and , National Cancer Institute; , Information Management Services, Rockville; , National Institutes of Health; , National Human Genome Research Institute, Bethesda; , Scientific Consulting Group, Gaithersburg, MD; , RTI International, Research Triangle Park, NC; , City of Hope, Duarte, CA; , Harvard Medical School and Brigham and Women's Hospital; , Dana-Farber Cancer Institute, Boston, MA; , University of Vermont Health Network and the University of Vermont, Burlington, VT; , Georgetown University, Washington, DC; , American Society of Clinical Oncology, Alexandria, VA; and , American Cancer Society, Atlanta, GA.
Timothy S McNeel, , , , , , , and , National Cancer Institute; , Information Management Services, Rockville; , National Institutes of Health; , National Human Genome Research Institute, Bethesda; , Scientific Consulting Group, Gaithersburg, MD; , RTI International, Research Triangle Park, NC; , City of Hope, Duarte, CA; , Harvard Medical School and Brigham and Women's Hospital; , Dana-Farber Cancer Institute, Boston, MA; , University of Vermont Health Network and the University of Vermont, Burlington, VT; , Georgetown University, Washington, DC; , American Society of Clinical Oncology, Alexandria, VA; and , American Cancer Society, Atlanta, GA.
Lori Minasian, , , , , , , and , National Cancer Institute; , Information Management Services, Rockville; , National Institutes of Health; , National Human Genome Research Institute, Bethesda; , Scientific Consulting Group, Gaithersburg, MD; , RTI International, Research Triangle Park, NC; , City of Hope, Duarte, CA; , Harvard Medical School and Brigham and Women's Hospital; , Dana-Farber Cancer Institute, Boston, MA; , University of Vermont Health Network and the University of Vermont, Burlington, VT; , Georgetown University, Washington, DC; , American Society of Clinical Oncology, Alexandria, VA; and , American Cancer Society, Atlanta, GA.
Arnold L Potosky, , , , , , , and , National Cancer Institute; , Information Management Services, Rockville; , National Institutes of Health; , National Human Genome Research Institute, Bethesda; , Scientific Consulting Group, Gaithersburg, MD; , RTI International, Research Triangle Park, NC; , City of Hope, Duarte, CA; , Harvard Medical School and Brigham and Women's Hospital; , Dana-Farber Cancer Institute, Boston, MA; , University of Vermont Health Network and the University of Vermont, Burlington, VT; , Georgetown University, Washington, DC; , American Society of Clinical Oncology, Alexandria, VA; and , American Cancer Society, Atlanta, GA.
Donna R Rivera, , , , , , , and , National Cancer Institute; , Information Management Services, Rockville; , National Institutes of Health; , National Human Genome Research Institute, Bethesda; , Scientific Consulting Group, Gaithersburg, MD; , RTI International, Research Triangle Park, NC; , City of Hope, Duarte, CA; , Harvard Medical School and Brigham and Women's Hospital; , Dana-Farber Cancer Institute, Boston, MA; , University of Vermont Health Network and the University of Vermont, Burlington, VT; , Georgetown University, Washington, DC; , American Society of Clinical Oncology, Alexandria, VA; and , American Cancer Society, Atlanta, GA.
Richard L Schilsky, , , , , , , and , National Cancer Institute; , Information Management Services, Rockville; , National Institutes of Health; , National Human Genome Research Institute, Bethesda; , Scientific Consulting Group, Gaithersburg, MD; , RTI International, Research Triangle Park, NC; , City of Hope, Duarte, CA; , Harvard Medical School and Brigham and Women's Hospital; , Dana-Farber Cancer Institute, Boston, MA; , University of Vermont Health Network and the University of Vermont, Burlington, VT; , Georgetown University, Washington, DC; , American Society of Clinical Oncology, Alexandria, VA; and , American Cancer Society, Atlanta, GA.
Deborah Schrag, , , , , , , and , National Cancer Institute; , Information Management Services, Rockville; , National Institutes of Health; , National Human Genome Research Institute, Bethesda; , Scientific Consulting Group, Gaithersburg, MD; , RTI International, Research Triangle Park, NC; , City of Hope, Duarte, CA; , Harvard Medical School and Brigham and Women's Hospital; , Dana-Farber Cancer Institute, Boston, MA; , University of Vermont Health Network and the University of Vermont, Burlington, VT; , Georgetown University, Washington, DC; , American Society of Clinical Oncology, Alexandria, VA; and , American Cancer Society, Atlanta, GA.
Naoko I Simonds, , , , , , , and , National Cancer Institute; , Information Management Services, Rockville; , National Institutes of Health; , National Human Genome Research Institute, Bethesda; , Scientific Consulting Group, Gaithersburg, MD; , RTI International, Research Triangle Park, NC; , City of Hope, Duarte, CA; , Harvard Medical School and Brigham and Women's Hospital; , Dana-Farber Cancer Institute, Boston, MA; , University of Vermont Health Network and the University of Vermont, Burlington, VT; , Georgetown University, Washington, DC; , American Society of Clinical Oncology, Alexandria, VA; and , American Cancer Society, Atlanta, GA.
Helmneh M Sineshaw, , , , , , , and , National Cancer Institute; , Information Management Services, Rockville; , National Institutes of Health; , National Human Genome Research Institute, Bethesda; , Scientific Consulting Group, Gaithersburg, MD; , RTI International, Research Triangle Park, NC; , City of Hope, Duarte, CA; , Harvard Medical School and Brigham and Women's Hospital; , Dana-Farber Cancer Institute, Boston, MA; , University of Vermont Health Network and the University of Vermont, Burlington, VT; , Georgetown University, Washington, DC; , American Society of Clinical Oncology, Alexandria, VA; and , American Cancer Society, Atlanta, GA.
Jeffery P Struewing, , , , , , , and , National Cancer Institute; , Information Management Services, Rockville; , National Institutes of Health; , National Human Genome Research Institute, Bethesda; , Scientific Consulting Group, Gaithersburg, MD; , RTI International, Research Triangle Park, NC; , City of Hope, Duarte, CA; , Harvard Medical School and Brigham and Women's Hospital; , Dana-Farber Cancer Institute, Boston, MA; , University of Vermont Health Network and the University of Vermont, Burlington, VT; , Georgetown University, Washington, DC; , American Society of Clinical Oncology, Alexandria, VA; and , American Cancer Society, Atlanta, GA.
Gordon Willis, , , , , , , and , National Cancer Institute; , Information Management Services, Rockville; , National Institutes of Health; , National Human Genome Research Institute, Bethesda; , Scientific Consulting Group, Gaithersburg, MD; , RTI International, Research Triangle Park, NC; , City of Hope, Duarte, CA; , Harvard Medical School and Brigham and Women's Hospital; , Dana-Farber Cancer Institute, Boston, MA; , University of Vermont Health Network and the University of Vermont, Burlington, VT; , Georgetown University, Washington, DC; , American Society of Clinical Oncology, Alexandria, VA; and , American Cancer Society, Atlanta, GA.
Janet S de Moor, , , , , , , and , National Cancer Institute; , Information Management Services, Rockville; , National Institutes of Health; , National Human Genome Research Institute, Bethesda; , Scientific Consulting Group, Gaithersburg, MD; , RTI International, Research Triangle Park, NC; , City of Hope, Duarte, CA; , Harvard Medical School and Brigham and Women's Hospital; , Dana-Farber Cancer Institute, Boston, MA; , University of Vermont Health Network and the University of Vermont, Burlington, VT; , Georgetown University, Washington, DC; , American Society of Clinical Oncology, Alexandria, VA; and , American Cancer Society, Atlanta, GA.
Funding
NCI NIH HHS HHSN261201000086CNCI NIH HHS HHSN261201400011CNCI NIH HHS HHSN261201400011I
Abstract
Purpose: There are no nationally representative data on oncologists' use of next-generation sequencing (NGS) testing in practice. The purpose of this study was to investigate how oncologists in the United States use NGS tests to evaluate patients with cancer and to inform treatment recommendations. Methods: The study used data from the National Survey of Precision Medicine in Cancer Treatment, which was mailed to a nationally representative sample of oncologists in 2017 (N = 1,281; cooperation rate = 38%). Weighted percentages were calculated to describe NGS test use. Multivariable modeling was conducted to assess the association of test use with oncologist practice characteristics. Results: Overall, 75.6% of oncologists reported using NGS tests to guide treatment decisions. Of these oncologists, 34.0% used them often to guide treatment decisions for patients with advanced refractory disease, 29.1% to determine eligibility for clinical trials, and 17.5% to decide on off-label use of Food and Drug Administration-approved drugs. NGS test results informed treatment recommendations often for 26.8%, sometimes for 52.4%, and never or rarely for 20.8% of oncologists. Oncologists younger than 50 years of age, holding a faculty appointment, having genomics training, seeing more than 50 unique patients per month, and having access to a molecular tumor board were more likely to use NGS tests. Conclusion: In 2017, most oncologists in the United States were using NGS tests to guide treatment decisions for their patients. More research is needed to establish the clinical usefulness of these tests, to develop evidence-based clinical guidelines for their use in practice, and to ensure that patients who can benefit from these new technologies receive appropriate testing and treatment.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.